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Available online 5 March 2016Anti-drug antibodies may developwith biological therapies, possibly leading to a reduction of treatment efﬁcacy
and to allergic and other adverse reactions. Patients with Gaucher disease were tested for anti-drug antibodies
every 6 or 12 weeks in clinical studies of velaglucerase alfa enzyme replacement therapy, as part of a range of
safety endpoints. In 10 studies between April 2004 and March 2015, 289 patients aged 2–84 years (median
43 years) were assessed for the development of anti-velaglucerase alfa antibodies. Sixty-four patients were
treatment-naïve at baseline and 225 patients were switched to velaglucerase alfa from imiglucerase treatment.
They received velaglucerase alfa treatment for a median of 36.4 weeks (interquartile range 26.4–155.4 weeks).
Four patients (1.4%) became positive for anti-velaglucerase alfa IgG antibodies, two of whom had antibodies
thatwere neutralizing in vitro, but therewereno apparent changes in patients' platelet counts, hemoglobin levels
or levels of CCL18 and chitotriosidase, suggestive of clinical deterioration after anti-velaglucerase alfa antibodies
were detected, and no infusion-related adverse events were reported. Less than 2% of patients exposed to
velaglucerase alfa tested positive for antibodies and there was no apparent correlation between anti-
velaglucerase alfa antibodies and adverse events or pharmacodynamic or clinical responses.
© 2016 The Authors and Shire. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Seroconversion1. Introduction
Gaucher disease (GD) is an inheritedmetabolic disorder characterized
by a deﬁciency of the lysosomal enzyme β-glucocerebrosidase, which re-
sults in the accumulation of glucocerebroside inmacrophages throughout
the body. GD is classiﬁed into three clinical subtypes based on the absence
(type 1) or the presence and severity of central nervous systemmanifes-
tations (types 2 and 3). The non-neuronopathic manifestations observedrse event; CCL18, chemokine
e; ELISA, enzyme-linked im-
rapy; GD, Gaucher disease;
rgent adverse event.
ited Metabolic Diseases—Adult
niversity Hospital, Eccles Street,
, hadhami.baili@laposte.net
iroy@jikei.ac.jp (H. Ida),
(Y. Qin), yqiu@shire.com
(A. Zimran).
lsevier Inc. This is an open access artin all clinical subtypes include thrombocytopenia, anemia, splenomegaly,
hepatomegaly and diverse pathological changes in bone and bone mar-
row [1].
Long-term enzyme replacement therapy (ERT) with exogenous
glucocerebrosidase has been shown to be effective for the systemic
features of GD [2–5]. Velaglucerase alfa is the only ERT preparation
that is produced in a human cell line and, like the ﬁrst placental-
derived enzyme (alglucerase), it has an amino acid sequence identical
to the naturally occurring human glucocerebrosidase [6]. To date, ERT
with velaglucerase alfa has been studied in over 300 patients in six in-
terventional clinical trials, three extension studies and an investiga-
tional new drug treatment protocol, providing longitudinal data of
up to 7 years [7–17]. The other enzymes, imiglucerase and
taliglucerase alfa, are manufactured differently, using non-human
mammalian and plant cell lines in culture, respectively. Their amino
acid sequences are not identical to the natural human enzyme. More-
over, there are apparent structural differences in the glycosylation pat-
terns of these enzymes, although the clinical signiﬁcance of this is
uncertain [2,18–20].icle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
38 G.M. Pastores et al. / Blood Cells, Molecules and Diseases 59 (2016) 37–43Anti-drug antibodies (ADAs) are known to develop with biological
therapies, which may lead to a reduction of treatment efﬁcacy and the
occurrence of allergic and other adverse reactions [21]. ADAs have
been reported in 15% of patients with type 1 GD receiving imiglucerase
during the ﬁrst year of treatment; patients testing positive for anti-
imiglucerase antibodies may be more likely to have hypersensitivity-
type reactions [22]. ADAs have also been reported in patients with
type 1 GD treatedwith taliglucerase alfa; 13 to 53% of patients in clinical
studies tested positive [4]. Because ADA test results may be affected by
assay methodology, underlying diseases, concomitant medications and
other factors, frequencies of seroconversion (i.e., development of anti-
bodies) between products may not be comparable [4].
The immunogenic potential of therapeutic proteins is dependent on
many product-speciﬁc factors, including protein sequence or post-
translational modiﬁcations, and host-speciﬁc factors [23–25]. Correla-
tions have been observed between lysosomal storage disease genetic
mutations, endogenous enzyme activity levels in patients with lyso-
somal storage diseases, and the development of neutralizing ADAs to
exogenous therapeutic enzymes [26].
Patients were tested for anti-velaglucerase alfa antibodies through-
out the velaglucerase alfa GD clinical study program as part of a wide
range of safety endpoints.Wehave calculated the percentage of patients
who developed anti-velaglucerase alfa antibodies in the clinical study
program and evaluated the clinical and pharmacodynamic responses
in these patients.2. Methods
Ten clinical studies conducted between April 2004 and March 2015
were included in this analysis: six clinical trials, an expanded access
treatment protocol and three extension studies (Fig. 1) [7,8,10–17]. All
studies were conducted in accordance with ICH Good Clinical Practice
guidelines and local regulations, and written informed consent was
obtained from all patients.Fig. 1. Study designs and safety populations in velaglucerase alfa clinical studies to date. Treat
considered naïve because they had not received a GD-speciﬁc treatment for at least 12–30 moPatients with a diagnosis of GD aged at least 2 years (or at least
18 years in the phase I/II trial) received ERT as a 60-min intravenous en-
zyme infusion, administered every other week by a healthcare profes-
sional. Except for one comparator arm that received imiglucerase in a
non-inferiority trial, all patients in velaglucerase alfa studies were
assigned and received velaglucerase alfa at a dose between 15 and
60 U/kg.
Pre-medications such as antihistamines and corticosteroids, to
prevent or mitigate potential infusion-related reactions, were
allowed in patients who were pre-medicated during their previous
imiglucerase treatment and as needed, e.g., in patients experienc-
ing recurrent infusion-related reactions.
2.1. Study assessments
In the velaglucerase alfa clinical studies, blood was sampled every
2–12 weeks to measure the hemoglobin concentration and platelet
count. In all studies except the treatment access protocol (HGT-GCB-
058), bloodwas also sampled (every 2–25weeks) for plasmabiomarker
assays. The only study objective of HGT-GCB-058was to assess the safe-
ty of velaglucerase alfa, so indicators of efﬁcacy, like biomarkers, were
not measured (hematology testing in HGT-GCB-058 was part of the
safety evaluation).
Patients were monitored for adverse events (AEs) throughout the
studies and required to undergo a range of safety assessments including
physical examinations, measurement of vital signs at infusion visits,
hematology and clinical chemistry tests and serum ADA testing.
Other assessments were conducted in the velaglucerase alfa clinical
studies which are not included in this analysis but are described else-
where [7,8,10–16,27].
2.2. Antibody testing
Serum samples were assessed for anti-velaglucerase alfa antibodies
at Shire (Bioanalytical and Biomarker Development Department),ment-naïve = patient who had never received ERT or any GD-speciﬁc treatment or was
nths. GD1, type 1 Gaucher disease; GD3, type 3 Gaucher disease; yo, years old.
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39G.M. Pastores et al. / Blood Cells, Molecules and Diseases 59 (2016) 37–43except in one trial (HGT-GCB-068) and in one extension study (HGT-
GCB-091), wherein samples were analyzed at a contract research labo-
ratory designated by Shire (Tandem Labs, A LabCorp Company, West
Trenton, NJ, USA), following a decision made by Shire in 2013 to out-
source patient sample testing [8,28,29]. Details of the methods used at
the Shire Bioanalytical and Biomarker Development laboratory for the
earliest, phase I/II studies (TKT025 and TKT025EXT) and for subsequent
studies have been published [8,28].
Samples were taken at screening or baseline and then approximate-
ly every 6 or 12 weeks. To screen for the presence of anti-velaglucerase
alfa antibodies, electrochemiluminescence (ECL) bridging assays were
used, except in the earliest, phase I/II clinical trials in which an
enzyme-linked immunosorbent assay (ELISA) format was used (ELISA
was used only in TKT025 and TKT025EXT; the switch to the ECLmethod
improved throughput and brought the assays up to industry standards
at the time).
Samples that were positive on screening underwent additional test-
ing. The conﬁrmatory methods described here relate to the studies in
which there were positive screening tests. In the treatment access pro-
tocol HGT-GCB-058 and the extension study HGT-GCB-044, the conﬁr-
matory tests were a radioimmunoprecipitation (RIP) assay for IgG
antibodies and an ECL assay for IgE antibodies. In HGT-GCB-044, ECL
assays for IgM and IgA antibodies were conducted as well. Antibody
titers (in ng/mL) for conﬁrmed positive samples were determined
from the calibration curves run on the same plates in the bridge assay.
In trial HGT-GCB-068, the conﬁrmatory step was a drug competition
format using ECL; isotypes were not determined and titers were report-
ed as the maximum dilution factor by which a sample could be diluted
and remain positive (signal above the assay cut point). The conﬁrmato-
ry testingwas different in HGT-GCB-068 becausewhen antibody testing
was outsourced to a contract research laboratory, the ADA testing
scheme was made simpler and thus more suitable for routine patient
care. The new methods are at least as sensitive as the previous Shire
methods and ADA testing results from these two testing facilities are
highly comparable to each other based on a bridging study [29].
Samples conﬁrmed as positive for anti-velaglucerase alfa antibodies
were analyzed for neutralizing activity using a neutralizing antibody
assay.
Patients were tested for anti-imiglucerase antibodies at screening or
baseline in ﬁve of the six clinical trials, in the extension study HGT-GCB-
044 (patients who had completed study HGT-GCB-039), and in the
treatment access protocol. Patients in the clinical trial HGT-GCB-068
were not tested for anti-imiglucerase antibodies because the whole
study population had never been exposed to imiglucerase. The antibody
detection methods for anti-velaglucerase alfa antibodies and anti-
imiglucerase antibodies were analogous.
2.3. Analysis and summary
Patients with antibody assessments conducted at baseline and at
least once after baseline were included in this analysis. No statistical
tests were performed.
Serial measurements of hemoglobin concentration, platelet count
and the disease biomarkers chemokine (C–C motif) ligand 18 (CCL18)
and chitotriosidase were plotted for each patient who tested positive
for anti-velaglucerase alfa antibodies, to look for trends in the clinical
and pharmacodynamic responses before and after antibodies were de-
tected. Chitotriosidase values were normalized, as previously described
[12,14], in patients found to have a common 24-base pair duplication in
one copy of their chitotriosidase genewhich results on average in a 50%
reduction in activity [30].
Adverse event listings were reviewed for infusion-related reactions
and other treatment-emergent adverse events (TEAEs). Infusion-
related reactions were deﬁned as AEs that began within 12 h of the
start of the infusion and were judged as possibly or probably related
to the study drug.
40 G.M. Pastores et al. / Blood Cells, Molecules and Diseases 59 (2016) 37–43We also descriptively summarized data in patients who were
found to have anti-imiglucerase antibodies that cross-reacted with
velaglucerase alfa.
3. Results
In the clinical studies, 333 patients received at least one full or partial
dose of velaglucerase alfa. In total, 289 patients exposed to velaglucerase
alfa were assessed for the development of anti-velaglucerase alfa anti-
bodies (i.e., assessed at baseline and at least once afterwards, before
discontinuing from study) and included in this analysis, comprising
142 male and 147 female patients. The patients were aged between 2
and 84 years at baseline (median 43 years).
Of 289 patients, 281 had a diagnosis of type 1 GD; however, of these,
two were subsequently found to be carriers (i.e., only one disease allele
has been identiﬁed) [10]. Eight patients from two studies had type 3 GD
(Fig. 1).
Sixty-four patients had never received ERT or any GD-speciﬁc treat-
ment before their ﬁrst dose of velaglucerase alfa or were considered
treatment-naïve because they had not received a GD-speciﬁc treatment
for at least 12 months. The remaining 225 patients were switched to
velaglucerase alfa ERT from imiglucerase; in the clinical trials, patients
switched to velaglucerase alfa in a timely fashion (i.e., without a break
in treatment schedule), but in the treatment access protocol which was
initiated during a global shortage of imiglucerase, some patients wereFig. 2. Platelet count, hemoglobin concentration, CCL18 level and chitotriosidase activity over t
the average of two measurements within the same week. 12-year-old female and 26-year-ol
measurements have been multiplied by two. Dashed vertical lines mark the time points at w
the 3-year-old patient and the 68-year-old patient, 53 weeks for the 26-year-old patient and 7switched to velaglucerase alfa following a treatment interruption (infor-
mation on the duration of treatment interruptions was not collected).
Overall, 37 of 289 patients (12.8%) tested positive for antibodies to
imiglucerase at the baseline or screening visit: three patients each in
two of the clinical studies (TKT034 and the extension study HGT-GCB-
044) and 31 patients in the treatment access protocol (HGT-GCB-058),
all of whom were previously treated with imiglucerase [12,13,15].
The longest period of velaglucerase alfa exposurewas 386.6weeks, in-
cluding time in an extension study. Themedian duration was 36.4 weeks
(interquartile range 26.4–155.4 weeks).3.1. Development of anti-velaglucerase alfa antibodies
Four (1.4%) of 289 patients tested positive for anti-velaglucerase alfa
antibodies after exposure to velaglucerase alfa (Table 1): two of 64
patients who were treatment-naïve at baseline (3.1%) and two of 225
patients switched from imiglucerase (0.9%).
In the two patients who were treatment-naïve at baseline, the anti-
velaglucerase alfa antibody titers decreased over time, after they tested
positive. Between the ﬁrst positive test result and the end-of-study as-
sessment in the 3-year-old patient (Table 1), the IgG titer fell from
640 to 40. Between the ﬁrst positive test and the last positive test in
the 26-year-old patient who was in fact only transiently antibody-
positive, the IgG concentration fell from 346 ng/mL to 97 ng/mL. Theime in patients who tested positive for anti-velaglucerase alfa antibodies. Some values are
d male were heterozygous for the chitotriosidase gene mutation, so their chitotriosidase
hich the patients ﬁrst tested positive for anti-velaglucerase alfa antibodies: 13 weeks for
7 weeks for the 12-year-old patient.
41G.M. Pastores et al. / Blood Cells, Molecules and Diseases 59 (2016) 37–43anti-velaglucerase alfa antibodies detected in the 26-year-old patient
had in vitro neutralizing activity.
In the two patients who were switched from imiglucerase, the
IgG anti-velaglucerase alfa antibody titers at their ﬁrst positive
tests and at their last study assessments were 258 ng/mL (week
13) and 301 ng/mL (week 25) in the 68-year-old patient, and
1207 ng/mL (week 77) and 8440 ng/mL (week 161) in the 12-year-
old patient. The anti-velaglucerase alfa antibodies detected in the
12-year-old patient had in vitro neutralizing activity.
Prior to receiving velaglucerase alfa (at baseline of study TKT034 or
HGT-GCB-058), both of the patientswhowere switching from imigluce-
rase treatment had high titers of non-neutralizing anti-imiglucerase
antibodies. The anti-imiglucerase IgG titers were 583,161 ng/mL in the
68-year-old patient and 240,816 ng/mL in the 12-year-old patient.
Finally, of note, the 68-year-old patient who was switching from
imiglucerase treatment was positive for IgE anti-imiglucerase antibod-
ies, in addition to IgG antibodies, at the screening visit for the study
HGT-GCB-058.
3.2. Treatment efﬁcacy in anti-velaglucerase alfa antibody-positive patients
Platelet count, hemoglobin concentration, and levels of CCL18 and
chitotriosidase all improved during treatment with velaglucerase alfa in
the two patients who were treatment-naïve at baseline and they were
generally maintained in the two patients who were switched from ERT
with imiglucerase. This is consistent with the overall results from the re-
spective clinical study populations, HGT-GCB-044,−058 and−068 [12,
15,17]. Therewere no apparent trends suggestive of clinical deterioration
after anti-velaglucerase alfa antibodies were detected (Fig. 2).
3.3. Adverse events in anti-velaglucerase alfa antibody-positive patients
No infusion-related AEs were reported for any of the four patients
who became positive for antibodies to velaglucerase alfa. One patient
(12-year-old switchpatient) received paracetamol during the extension
study HGT-GCB-044 as pre-medication to prevent possible infusion re-
actions. Two patients did not receive any pre-medications at any time.
Data on concomitant medication use were not collected for the fourth
patient (68-year-old switch patient).
Three of the four patients experienced at least one TEAE; a total of 18
non-serious AEs were reported that were considered neither possibly
nor probably related to the study drug (Supplementary Table 1). One
patient had no TEAEs (68-year-old switch patient who tested positive
after 13 weeks and received the last study infusion in week 33).
None of these patients discontinued from study participation due to
an AE.Table 2
Cross-reactivity in anti-imiglucerase antibody-positive patients in the treatment access protoco
Cross-reactive anti-imiglucerase
antibodies
Screening visit before study
Patients with available data 12
Anti-imiglucerase antibodies 12
Anti-velaglucerase alfa antibodies (cross-reactive) 12
Neutralizing enzyme activity
Negative for neutralizing activity 2
Neutralizing anti-imiglucerase antibodies 9a
Neutralizing anti-velaglucerase alfa antibodies 10a
Anti-imiglucerase IgG titer range, ng/mL 528 to 1,829,242
During clinical study
Patients with available data 10
Anti-velaglucerase alfa antibodies 9b
a One of 10 patients whose sera had neutralizing activity had antibodies that were neutraliz
b One patient who tested positive for anti-velaglucerase alfa antibodies at the screening visit
anti-velaglucerase alfa antibodies during the study.
c One patient developed anti-velaglucerase alfa antibodies during the study, after exposure3.4. Patients with cross-reactive anti-imiglucerase antibodies
Across the velaglucerase alfa clinical studies, 13 of 333 patients were
found to have anti-imiglucerase antibodies that were cross-reactive
with velaglucerase alfa (although not all patients in the trials were test-
ed for anti-imiglucerase antibodies, of the 289 patients with post-
baseline follow-up antibody data, 11 patients were found to have
cross-reactive anti-imiglucerase antibodies). Of these 13 patients, one
patient was treatment-naïve at the baseline of study HGT-GCB-039
and became positive for both anti-imiglucerase antibodies and anti-
velaglucerase alfa antibodies during the 9-month study period in
which he received imiglucerase treatment [11]. The remaining 12
patients were participants in the treatment access protocol HGT-GCB-
058 who were switching from imiglucerase to velaglucerase alfa treat-
ment; they tested positive for both anti-imiglucerase antibodies and
anti-velaglucerase alfa antibodies at the screening visit for HGT-GCB-
058 [15]. These 13 patients had no previous exposure to velaglucerase
alfa, so positivity for anti-velaglucerase alfa antibodies was attributed
to cross-reaction in the assay.
The patient treated with imiglucerase in study HGT-GCB-039 ﬁrst
tested positive at week 13 for IgG anti-imiglucerase antibodies, which
cross-reacted in the anti-velaglucerase alfa antibody assay. He remained
in the study for another 10 weeks and he was still positive for antibodies
to both imiglucerase and velaglucerase alfa at his end-of-study antibody
assessment at week 22, despite never having been exposed to
velaglucerase alfa. In this patient, the anti-imiglucerase antibodies and
anti-velaglucerase alfa antibodies were both neutralizing in vitro; his
hematologic variables nevertheless improved in the weeks after he
ﬁrst tested positive. However, he ultimately withdrew consent due to
multiple infusion-related reactions [11].
In the treatment access protocol HGT-GCB-058, a total of 37 patients
tested positive for anti-imiglucerase antibodies at the screening visit, 12
of whom had cross-reactive antibodies. Thirty-one patients had follow-
up antibody data; of these, 10 patients had cross-reactive antibodies
(Table 2). The most notable difference between the patients with
cross-reactive anti-imiglucerase antibodies and those with non-cross
reactive anti-imiglucerase antibodies was the proportion testing posi-
tive for neutralizing enzyme activity (Table 2). In any case, there was
no apparent difference in the occurrence of TEAEs or infusion-related
AEs between ADA-positive switch patients and ADA-negative switch
patients in the HGT-GCB-058 study population [15].4. Discussion
Anti-velaglucerase alfa antibodies were assayed in patients
participating in the velaglucerase alfa clinical studies because thel HGT-GCB-058 (37 patients switched from imiglucerase).
Non-cross-reactive anti-imiglucerase
antibodies
All anti-imiglucerase antibody-positive
patients
25 37
25 37
0 12
23 25
2 11
n/a 10
71 to 583,161 71 to 1,829,242
21 31
1c 10
ing only to velaglucerase alfa.
(whichwere cross-reactive anti-imiglucerase antibodies) subsequently tested negative for
to velaglucerase alfa (the 68-year-old switch patient discussed elsewhere in this report).
42 G.M. Pastores et al. / Blood Cells, Molecules and Diseases 59 (2016) 37–43development of ADAs is known to occur with biological therapies,
including ERTs [21,22]. Theoretically, ADAs may reduce treatment
efﬁcacy and lead to allergic and other adverse reactions [21].
Less than 2% of patients exposed to velaglucerase alfa tested positive
for antibodies. Velaglucerase alfa's overall seroconversion rate was
lower than that reported with imiglucerase (15%), and this is consistent
with the ADA results from the head-to-head trial, HGT-GCB-039, that
compared velaglucerase alfa with imiglucerase [11,22]. In the HGT-
GCB-039 trial, except for the drug itself used to capture and detect anti-
bodies, the analytical platform for analyzing anti-imiglucerase antibod-
ies was identical to the platform for analyzing anti-velaglucerase alfa
antibodies. Four patients exposed to imiglucerase developed anti-
imiglucerase antibodies whereas none in the velaglucerase alfa treat-
ment group tested positive for ADAs. The major limitation of the HGT-
GCB-039 study was the study population size (34 patients). We exam-
ined a large group of patients in this analysis, but the antibody testing
data was based on analytical methods that were different from those
used in studies of imiglucerase (or taliglucerase alfa). At any rate, the
agreement between the small controlled study (HGT-GCB-039) and
this large data collection is noteworthy.
Among the small group of patients who tested positive for anti-
velaglucerase alfa antibodies, there was no apparent correlation
between the development of anti-velaglucerase alfa antibodies and
AEs or pharmacodynamic or clinical responses, including the two pa-
tients with antibodies that were neutralizing in vitro. In general, being
positive for velaglucerase alfa ADAs is not a reliable predictor for drug-
related hypersensitivity reactions. However, according to a review of
real-world global safety data on imiglucerase use, patients who are pos-
itive for anti-imiglucerase antibodies may have an increased risk of
experiencing a hypersensitivity-type reaction since hypersensitivity
symptoms were reported by almost half of antibody-positive patients
[22]. Anti-imiglucerase antibodies were generally detected within
6 months of initiating treatment and did not appear to have any effect
on efﬁcacy variables [22]. Hypersensitivity reactions have also been ob-
served in patients testing positive for anti-taliglucerase alfa antibodies
in clinical trials, including the rare occurrence of anaphylactic reactions
[4]. The number of patients developing neutralizing anti-taliglucerase
alfa antibodies was too small to determine a relationship with treat-
ment response [4].
Anti-velaglucerase alfa antibody titers were much lower than anti-
imiglucerase antibody titers in the two patients who were switched
from imiglucerase treatment and developed anti-velaglucerase alfa
antibodies. In addition, in the other two patients who developed
anti-velaglucerase alfa antibodies, decreasing antibody titers were ob-
served, for which we have no certain explanation; however, supposed
‘immune tolerance’ with continued regular enzyme replacement has
also been observed in patients receiving ERT for Pompe disease and
mucopolysaccharidosis I [31,32].
As previously discussed [15], the ADA results of the treatment access
protocol (HGT-GCB-058) suggest that neutralizing anti-imiglucerase
antibodies are likely to cross-react with velaglucerase alfa.4.1. Limitations of analysis
Patients were not all exposed to velaglucerase alfa for the same
period of time in the clinical studies. Our results suggest that patients
can become antibody-positive at any time in the ﬁrst 18 months of
drug exposure, and half of the cohort in the current report received
the study drug for less than 9 months.
Because only four patients tested positive for anti-velaglucerase alfa
antibodies, we had a very small group in which to evaluate the clinical
effect of seroconversion. One of the patients who tested antibody-
positive was observed for only 12 weeks after the ﬁrst positive test re-
sult, so the evaluable clinical data were particularly limited in that
patient.Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bcmd.2016.03.004.
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